PathoQuest Raises $4.96M in Funding

PathoQuest, a Paris, France-based molecular diagnostics company, raised about $4.96m in funding.

Backers included new investors Idinvest and Aurinvest, and existing investor Kurma Life Science Partners.

Founded in 2010 as a spin-off of the Pasteur Institute and the ENVA (Ecole Nationale Veterinaire d’Alfort) and led by Prof. Marc Eloit, president and CSO and Luc Boblet, CEO, PathoQuest develops a Next Generation Sequencing cloud-based diagnostic assay for infectious diseases, a bioinformatics workflow that is designed to assist the diagnostic decision-making.

The company, which had previously raised €2m in March 2011, intends to use the financing for the first clinical study of a new disgnostic assay, which will target diagnosis of severe multi-etiological-based infectious episodes in immuno-compromised patients.
PathoQuest intends to launch a first commercial product in 2015, following an extension of this clinical trial in the US in the coming months.



Join the discussion